Custom hyaluronic acid-conjugated lipid nanoparticle (HA-LNP) development for CD44-related targeting studies, ligand-lipid conjugation, RNA-compatible formulation, surface characterization, and functional delivery evaluation.
Hyaluronic acid (HA) is a naturally occurring glycosaminoglycan that can interact with CD44 and other HA-binding receptors. Displaying HA on lipid nanoparticles provides a way to study receptor-associated delivery to selected tumor cells, activated macrophages, and other CD44-expressing models. Its performance depends on HA molecular weight, ligand accessibility, lipid anchor design, receptor expression, and the underlying nanoparticle formulation.
HA conjugation is more than adding a hydrophilic coating. HA can change particle diameter, surface charge, colloidal stability, payload retention, and biological interactions. A successful design must preserve the useful properties of the LNP core while presenting HA in a form that target cells can recognize. CD44 expression alone does not establish selective delivery, so matched controls and payload-function assays are important.
BOC Sciences provides integrated targeted LNP development, from HA ligand selection and chemical modification to formulation screening, particle analysis, and receptor-related cellular evaluation. We tailor HA-LNPs to siRNA, mRNA, other nucleic acids, small molecules, and selected protein or imaging payloads, helping research teams select candidates using measurable formulation and biological data.
HA-Modified Lipid Nanoparticle Structure Illustration
Our service portfolio covers HA chemistry, nanoparticle assembly, surface modification, and CD44-oriented delivery testing. Each work package can be performed individually or combined into a comparative formulation-development program, depending on the client's payload and target-cell model.
We select suitable HA structures and design lipid-linked derivatives to control how HA is attached to, and displayed on, an LNP surface.
We help identify how HA should be attached to the nanoparticle, rather than applying a single surface-coating method to every formulation.
HA functionalization and the LNP core are optimized together to balance receptor access with payload loading and intracellular delivery.
We evaluate both the nanoparticle core and the HA surface layer so that changes in targeting behavior can be interpreted alongside formulation data.
We investigate whether an HA coating improves cell-associated delivery and whether any uptake advantage translates into payload activity.
We refine preparation and post-processing variables to obtain interpretable and reproducible HA-LNP batches for comparative research.
The right HA attachment strategy depends on the core lipid system, payload sensitivity, available reactive groups, and desired surface presentation. The first four methods below describe how HA is linked to a surface; co-assembly and post-insertion describe when a preformed HA-lipid conjugate is introduced. These are complementary design choices rather than six mutually exclusive chemistries.
Covalent coupling links HA to amine- or otherwise reactive lipid components using a defined chemical bond. A commonly explored route activates carboxyl groups along the HA chain with EDC/NHS, followed by reaction with an amine-functionalized lipid or spacer such as DSPE-PEG-NH2 to form an amide linkage.
Negatively charged HA can associate with a positively charged lipid-particle surface through electrostatic attraction. In selected systems, HA is deposited directly or as the final layer of a multilayer coating containing a cationic intermediate.
In affinity-based assembly, appropriately functionalized HA is attached through a strong recognition pair, such as biotinylated HA with an avidin-family bridging component on a biotin-functionalized lipid surface. The connection is noncovalent but highly specific to the chosen binding pair.
Bioorthogonal coupling creates a selective covalent linkage between separately functionalized HA and an LNP surface. For example, azide-functionalized HA can react with a DBCO-functionalized lipid through strain-promoted cycloaddition without adding a copper catalyst.
Pre-synthesized HA-lipid conjugates are incorporated while the lipid and payload components form nanoparticles. A compatible HA-lipid anchor is introduced during the formulation process, allowing HA presentation to be built into the particle from the outset.
HA is first attached to a lipid anchor, and the resulting HA-lipid conjugate is then contacted with previously formed LNPs. Under suitable conditions, the hydrophobic anchor associates with accessible lipid regions at the particle surface, leaving the HA chain displayed externally.
For all six approaches, BOC Sciences can evaluate HA molecular weight and surface coverage alongside PEG shielding. Our related LNP PEG-lipid optimization services help identify whether a candidate has sufficient ligand accessibility while maintaining useful particle stability.
Share your lipid composition, HA molecular-weight range, payload, and target-cell model. We can help compare feasible coupling routes and define the characterization needed to select one.
HA provides a versatile, chemically modifiable surface ligand for lipid nanoparticles. Its potential benefits depend on the receptor profile and biological environment, making rational design and comparative testing essential.
CD44-Associated Target-Cell Recognition
Surface-accessible HA can engage CD44 on selected tumor cells and activated immune-cell models. Compared with otherwise matched unmodified LNPs, this creates an opportunity to investigate receptor-associated uptake. Because CD44 also occurs on healthy cells and HA interacts with additional receptors, targeting must be demonstrated in the intended model rather than assumed.
Tunable Molecular Weight and Surface Presentation
HA chain length, grafting density, linker structure, and PEG-lipid content provide multiple design variables. Screening these together helps identify useful compromises between receptor access, steric effects, particle diameter, and stability. Increasing HA chain length or coverage is not automatically advantageous.
Compatibility with Different Payload Strategies
HA modification can be considered for RNA-loaded LNPs and selected lipid systems carrying other payload classes. Post-insertion, for example, allows the ligand-modification stage to be separated from initial nucleic-acid encapsulation. Actual compatibility is verified by payload retention and functional-delivery measurements for each formulation.
Adaptable Surface and Responsive-Release Designs
The HA chain contains chemical groups suitable for derivatization and can be incorporated into more complex surface architectures. Depending on the design, HA degradation or removal may be explored as part of an enzyme-responsive system. Such behavior requires direct testing because HA coating alone does not guarantee controlled release or enhanced tissue penetration.
BOC Sciences develops HA-modified LNPs for many payload types used in CD44-targeted delivery research. Each payload needs a suitable loading strategy, particle design, and functional readout. We help match HA surface engineering with the payload type and the target-cell model.
| Payload Type | Supported Uses & HA-LNP Development Considerations | Request Information |
|---|---|---|
| HA-LNP Development for siRNA | Suitable for CD44-targeted gene-silencing studies, tumor cell knockdown, and inflammatory pathway research. Development focuses on siRNA encapsulation, free RNA reduction, HA density, CD44-related uptake, and knockdown comparison using matched control LNPs. Related work is supported by our lipid nanoparticles for siRNA delivery platform. | Inquiry |
| HA-LNP Development for mRNA and Reporter RNA | Designed for reporter expression, protein expression, and formulation comparison studies. Development considers mRNA integrity, encapsulation efficiency, HA surface exposure, particle stability, and expression readouts in CD44-expressing cell models. See our lipid nanoparticles for mRNA delivery services. | Inquiry |
| HA-LNP Development for circRNA and Self-Amplifying RNA | Applicable to RNA delivery systems that need strong payload protection and sustained target-cell expression. BOC Sciences supports lipid nanoparticles for circRNA delivery with HA surface modification, stability evaluation, and cell-based expression testing. | Inquiry |
| HA-LNP Development for gRNA/mRNA Combination | Supports co-loaded nucleic acid systems that require ratio control and particle uniformity. We evaluate co-encapsulation behavior, HA-lipid compatibility, particle attributes, and functional readouts under matched control conditions. | Inquiry |
| HA-LNP Development for Protein and Peptide | Suitable for protein antigens, enzymes, peptides, binding proteins, and functional protein payloads used in CD44-targeted delivery research. Formulation work focuses on mild loading conditions, aggregation control, and HA-dependent uptake evaluation. This draws on our protein encapsulation in LNPs experience. | Inquiry |
| HA-LNP Development for Small Molecule | Designed for hydrophobic, amphiphilic, or ionizable small molecules used in CD44-targeted delivery research. We consider drug-lipid compatibility, loading method, leakage control, particle stability, HA modification, and release behavior, supported by hydrophobic payload encapsulation in LNPs. | Inquiry |
| HA-LNP Development for Fluorescent and Imaging | Supports fluorescent dyes, labeled RNA, labeled proteins, and other tracking payloads used to study HA-LNP uptake, intracellular localization, and distribution trends. Our fluorescent-labeled lipid nanoparticles capabilities can be applied directly. | Inquiry |
| HA-LNP Development for Custom Payload | Developed for unusual payloads, multiple payload systems, or early feasibility studies. We evaluate payload compatibility, loading sequence, HA modification route, particle stability, and target-cell delivery performance. | Inquiry |
Tell us your payload, target cell, and delivery goal, and BOC Sciences will propose an HA surface strategy that fits your project.
An HA-LNP may be well characterized chemically yet still perform poorly in a target-cell assay. We investigate formulation and biological factors together and use comparison studies to identify the step limiting performance.
Weak CD44-Related Uptake
HA may be hidden by PEG, presented too close to the lipid surface, or used with cells expressing insufficient accessible CD44. We compare HA molecular weights, spacers, coating levels, and receptor-expression controls to identify a more suitable surface design.
Particle Aggregation After HA Modification
Long HA chains, excessive grafting, and multiple attachment points may increase apparent particle size or promote interparticle association. We adjust conjugation extent, polymer length, lipid balance, and purification while following size and PDI.
Reduced RNA Encapsulation or Retention
Introducing HA-lipid during particle formation can disrupt an established RNA-loading process. We compare co-assembly with post-insertion, test relevant HA-lipid input levels, and measure encapsulation, unbound RNA, and RNA integrity.
Uncertain HA Attachment and Coating Stability
Size and surface-charge changes do not distinguish covalently attached HA from loosely associated polymer. We incorporate separation, ligand quantification, and retention studies before interpreting targeting-related assays.
Unclear CD44 Specificity
Cellular HA recognition can involve multiple receptors, while nanoparticles may also enter cells through nonspecific routes. We evaluate receptor expression, matched unmodified controls, suitable HA competition or blocking, and the consistency of uptake changes across cell models.
High Cellular Uptake but Weak Payload Function
Fluorescence accumulation is not equivalent to cytosolic cargo availability. We compare intracellular localization and reporter or silencing readouts, with optional LNP endosomal escape evaluation, to identify post-uptake limitations.
Tell us whether the bottleneck is HA attachment, particle size, RNA loading, CD44-related uptake, or functional delivery. BOC Sciences can design a focused troubleshooting study using matched formulations and clear analytical readouts.
Projects can begin with a client's existing LNP, HA-lipid material, or only a target delivery objective. We organize the work into four practical stages, refining the plan as formulation and cellular evidence becomes available.
We review the payload class, target-cell type, intended route of laboratory exposure, baseline LNP formulation if available, and desired biological readouts. CD44 expression, comparator cell models, RNA integrity requirements, and acceptable particle attributes help define the starting materials and the screening plan.
We select HA molecular-weight ranges, lipid anchors, coupling chemistry, and spacer architecture. We also compare co-assembly with post-insertion where feasible and identify how HA attachment, ligand exposure, and unbound polymer will be measured. The design includes matched unmodified LNP controls.
Candidate particles are prepared by a selected mixing or modification route. During LNP process optimization, we adjust lipid composition, HA-lipid input, PEG fraction, incubation conditions, purification, and buffer exchange, then compare particle size, PDI, HA levels, and payload retention before advancing candidates.
We assess selected candidates in the agreed cell models using receptor-expression measurements, uptake imaging or flow cytometry, and suitable blocking controls. RNA expression, gene knockdown, or another payload-specific endpoint is evaluated alongside particle data. Findings are summarized as a comparative dataset with documented design tradeoffs and suggested next experiments.
HA-LNPs are useful research platforms where HA-binding receptors, especially CD44, may influence cellular interactions. BOC Sciences develops formulations around defined cellular models and payload readouts rather than assuming that HA modification creates universal tissue specificity.
Challenge: A research team was developing an HA-modified LNP to deliver siRNA against an oncogenic target into a CD44+ breast cancer model (CD44-high breast cancer cell model). Their first HA-LNP used high-molecular-weight HA (about 250 kDa) and showed strong CD44 affinity in binding assays, but rapid hepatic accumulation, short circulation, and a broad PDI after preparation. Uptake selectivity over unmodified LNPs was weak, and knockdown was difficult to separate from non-specific effects.
Diagnosis: BOC Sciences found that the very high HA molecular weight increased hepatic clearance through HA receptors and raised solution viscosity, which made purification and batch consistency harder. The PEG-lipid level also partly masked the HA layer, and the formulation showed limited endosomal release, so high cellular uptake did not translate into functional silencing.
Solution: We screened three HA molecular weights (8 kDa, 50 kDa, and 250 kDa) across three surface densities and two PEG-lipid levels in matched LNP formulations. We also rebalanced the ionizable lipid, helper lipid, and cholesterol content. CD44 specificity was checked using CD44+ (CD44-high breast cancer cells) and CD44-low (MCF-7) models with free-HA competition, and endosomal release was assessed alongside knockdown.
Result: The selected candidate used about 50 kDa HA at roughly 1.5 mol% with a short PEG spacer and reduced PEG-lipid. It maintained an average particle size of about 95 nm with a PDI below 0.18 and siRNA encapsulation near 88%. CD44+ uptake increased about three-fold over the unmodified LNP, target knockdown reached about 70%, and hepatic accumulation was reduced. The client obtained a lead HA-LNP candidate with a clearer targeting mechanism.
Challenge: A biotechnology group wanted to deliver mRNA into activated macrophages, which upregulate CD44. Their first attempt used a post-insertion HA-LNP, but the HA layer desorbed in serum-containing medium and mRNA expression stayed low. The team needed stronger, more stable HA display together with reliable functional expression.
Diagnosis: BOC Sciences identified that the post-insertion HA desorbed under serum conditions, the HA density was too low for effective CD44 engagement, and the PEG layer over-shielded the ligand. The formulation also needed a better balance between stability and endosomal release.
Solution: We switched to a co-assembled HA-DSPE design so HA was anchored in the lipid bilayer during self-assembly. We screened HA molecular weight and density together with PEG-lipid ratio, then compared uptake and expression in LPS-activated and non-activated macrophage models using eGFP and luciferase mRNA readouts.
Result: The optimized co-assembled HA-LNP had an average size of about 110 nm and mRNA encapsulation above 85%. Selectivity for activated over non-activated macrophages increased about 2.5-fold, and reporter expression was consistently higher than the original post-insertion design. The client received a stable HA-LNP candidate and a clear formulation direction for macrophage-targeted mRNA delivery.
Integrated HA Chemistry and LNP DesignWe connect HA molecular-weight selection, lipid-anchoring chemistry, surface presentation, and particle formulation within a single development plan, reducing the disconnect between ligand synthesis and nanoparticle performance.
Method Selection Based on LNP ArchitectureWe assess whether covalent linkage, HA coating, co-assembly, or post-insertion suits the available lipid surface and payload, and explain the important tradeoffs before choosing a development route.
Payload-Compatible Formulation ScreeningOur workflows consider RNA encapsulation, small-molecule partitioning, particle stability, and HA surface accessibility together, helping research teams avoid solutions that improve coating appearance but impair payload function.
Mechanism-Informed Cellular EvaluationMatched controls, receptor-expression data, competition experiments, uptake imaging, and functional readouts help distinguish HA-associated cell entry from broader nanoparticle uptake.
Clear Formulation Comparison and Project OutputsWe organize candidate comparisons around agreed experimental endpoints, giving teams practical data to select a formulation, understand limitations, or decide which parameter to optimize next.
Hyaluronic acid (HA) can interact with CD44 receptors expressed on certain tumor cells, activated macrophages, and other cell populations. When HA is displayed on an LNP surface, it may promote receptor-associated binding and cellular uptake. However, targeting performance depends on HA molecular weight, surface density, PEG shielding, receptor accessibility, and the underlying lipid formulation. CD44 is also expressed by some normal cells, so HA modification does not automatically provide tumor-specific delivery. Researchers should compare HA-LNPs with unmodified controls, evaluate CD44 expression, and use receptor-blocking or competition experiments to determine whether enhanced uptake translates into functional payload delivery.
There is no universally optimal HA molecular weight for lipid nanoparticle modification. Lower-molecular-weight HA may offer easier formulation handling and reduced steric interference, while longer HA chains can provide multivalent receptor interactions but may also increase particle size, viscosity, and interactions with clearance-related receptors. The preferred molecular weight depends on the lipid composition, conjugation strategy, target-cell model, and intended payload. Researchers should compare several HA molecular-weight ranges while monitoring hydrodynamic diameter, polydispersity, surface HA accessibility, colloidal stability, and CD44-associated uptake. Functional delivery measurements are essential because stronger receptor binding does not necessarily produce better intracellular payload activity.
HA can be introduced onto lipid nanoparticles through several approaches, including covalent coupling, electrostatic adsorption, affinity-based attachment, click chemistry, co-assembly, and post-insertion. Covalent coupling provides a chemically stable connection, while electrostatic coating offers a relatively straightforward option for particles with positively charged surfaces. Affinity-based attachment supports modular assembly, and click chemistry enables selective covalent reactions between complementary functional groups. Co-assembly incorporates HA-lipid conjugates during nanoparticle formation, whereas post-insertion modifies previously prepared particles. The preferred method depends on the surface chemistry, payload sensitivity, ligand density requirements, and formulation stability. Each approach should be evaluated for HA retention, particle integrity, and functional delivery.
Yes. BOC Sciences supports HA surface modification of existing lipid nanoparticle formulations when their composition and physicochemical properties are compatible with the selected attachment strategy. Researchers can provide preformed LNPs, established lipid compositions, or HA-lipid conjugates for feasibility assessment. Depending on the formulation, our team can explore post-insertion, functional lipid-mediated covalent coupling, or other appropriate modification methods. We evaluate HA incorporation, particle size, surface charge, payload retention, and formulation stability before assessing CD44-related cellular uptake. If the original formulation is unsuitable for direct modification, we can investigate targeted adjustments to the lipid composition or surface architecture while preserving the project's intended delivery function.
BOC Sciences provides customized HA-LNP development services covering HA molecular-weight selection, HA-lipid conjugate synthesis, surface modification, formulation optimization, physicochemical characterization, and functional delivery evaluation. We support different payload types, including siRNA, mRNA, selected proteins, small molecules, and imaging agents. Our development workflow can include comparisons of HA conjugation methods, ligand density, PEG-lipid composition, payload encapsulation, and particle stability. For targeting studies, we can evaluate CD44 expression, cellular uptake, receptor-related interactions, intracellular localization, and payload-specific activity in suitable research models. Clients can engage us for individual technical challenges or integrated development projects based on their existing materials, target cells, and research objectives.
